Vorinostat Post-Transplant
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 15 patients (estimated)
- Tags
- Antimetabolites, Histone Deacetylase (HDAC) Inhibitor, Hypomethylating Agents (HMA), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1582
- NCT Identifier
- NCT03843528
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.